Cargando…

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

The current therapeutic landscape of luminal human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC) is fundamentally evolving, particularly in the advent of molecularly targeted therapies, such as inhibitors of mammalian target of rapamycin and cyclin-dependent kinas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rossi, Lorenzo, McCartney, Amelia, Risi, Emanuela, Malorni, Luca, Biganzoli, Laura, Di Leo, Angelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295674/ https://www.ncbi.nlm.nih.gov/pubmed/30574210 http://dx.doi.org/10.1177/1758835918815591

Ejemplares similares

The role of abemaciclib in treatment of advanced breast cancer
por: McCartney, Amelia, et al.
Publicado: (2018)

Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors
por: McCartney, Amelia, et al.
Publicado: (2020)

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial
por: Rossi, Lorenzo, et al.
Publicado: (2019)

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
por: Migliaccio, Ilenia, et al.
Publicado: (2021)

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
por: McCartney, Amelia, et al.
Publicado: (2019)

Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer
por: Vignoli, Alessia, et al.
Publicado: (2021)

Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification
por: McCartney, Amelia, et al.
Publicado: (2019)

Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial
por: Galardi, Francesca, et al.
Publicado: (2021)

PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer
por: Migliaccio, Ilenia, et al.
Publicado: (2022)

Palbociclib to reverse endocrine resistance in breast cancer: a TREnd in the right direction?
por: McCartney, Amelia, et al.
Publicado: (2018)

An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
por: Risi, Emanuela, et al.
Publicado: (2019)

The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy
por: De Santo, Irene, et al.
Publicado: (2019)

CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer
por: Di Cosimo, Serena, et al.
Publicado: (2020)

Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer
por: Zhao, Joseph J., et al.
Publicado: (2023)

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
por: Zattarin, Emma, et al.
Publicado: (2023)

Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best–Worst Scaling
por: Maculaitis, Martine C, et al.
Publicado: (2020)

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
por: Corona, Silvia Paola, et al.
Publicado: (2018)

Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
por: Davis, Andrew A., et al.
Publicado: (2023)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
por: Sammons, Sarah L., et al.
Publicado: (2017)

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
por: Cogliati, Viola, et al.
Publicado: (2022)

Are We Prepared for the CDK4/6 Revolution With HR+/HER2− Breast Cancers?: The Importance of Patient Adherence to Adjuvant Therapies
por: Azoz, Seyla, et al.
Publicado: (2023)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials
por: Gao, Hong-Fei, et al.
Publicado: (2021)

Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2− Breast Cancer at a Single Cancer Center
por: Knudsen, Erik S, et al.
Publicado: (2022)

Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study
por: D’Angelo, Alberto, et al.
Publicado: (2022)

Cellular senescence in the response of HR(+) breast cancer to radiotherapy and CDK4/6 inhibitors
por: Klapp, Vanessa, et al.
Publicado: (2023)

Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature
por: Stanciu, Ioana-Miruna, et al.
Publicado: (2023)

A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting
por: Di Donato, Samantha, et al.
Publicado: (2021)

A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer: a review of CDK inhibitors
por: Fernandes, Mariane Teodoro, et al.
Publicado: (2018)

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
por: Shikata, Shohei, et al.
Publicado: (2023)

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
por: Ascione, Liliana, et al.
Publicado: (2022)

Clinical Impact of CDK4/6 Inhibitors in De Novo or PR− or Very Elderly Post-Menopausal ER+/HER2− Advanced Breast Cancers
por: Tang, Hiu, et al.
Publicado: (2023)

Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer
por: Zhang, Jian, et al.
Publicado: (2021)

Immune effects of CDK4/6 inhibitors in patients with HR(+)/HER2(−) metastatic breast cancer: Relief from immunosuppression is associated with clinical response
por: Scirocchi, Fabio, et al.
Publicado: (2022)

The Association between Proton Pump Inhibitors and the Effectiveness of CDK Inhibitors in HR+/HER- Advanced Breast Cancer Patients: A Systematic Review and Meta-Analysis
por: Chang, Yu-Cheng, et al.
Publicado: (2023)

Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy
por: Bonechi, Martina, et al.
Publicado: (2018)

Gene expression profiling in prognosis of distant recurrence in HR-positive and HER2-negative breast cancer patients
por: Huang, Tzu-Ting, et al.
Publicado: (2018)

Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
por: Porte, B., et al.
Publicado: (2020)

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer
por: Park, Yeon Hee, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cg0bu27l7najoh2c26fa1jim2c